<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893217</url>
  </required_header>
  <id_info>
    <org_study_id>91232</org_study_id>
    <secondary_id>BEYOND pilot</secondary_id>
    <secondary_id>307000</secondary_id>
    <nct_id>NCT00893217</nct_id>
  </id_info>
  <brief_title>BEYOND Pilot Study</brief_title>
  <official_title>Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to valuate safety and tolerability of Betaseron.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of IFNB-1b 500 mcg given subcutaneously (SC) QOD compared with the standard dose of 250 mcg QOD in patients with RRMS.</measure>
    <time_frame>8 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaseron (Interferon beta-1b, BAY86-5046)</intervention_name>
    <description>250 mcg</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaseron (Interferon beta-1b, BAY86-5046)</intervention_name>
    <description>500 mcg</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosis of RRMS as defined by any of the following McDonald diagnostic criteria (McDonald&#xD;
        et al 2001; see Appendix 16.1.1 [(Protocol Appendix 5]):&#xD;
&#xD;
          -  Two relapses and objective clinical evidence (history or present) of at least 2&#xD;
             lesions&#xD;
&#xD;
          -  Two relapses and objective clinical evidence (history or present) of 1 lesion; and&#xD;
             dissemination in space, demonstrated by MRI (Barkhof/Tintoré criteria) or 2 MRI T2&#xD;
             lesions consistent with MS plus positive CSF.&#xD;
&#xD;
          -  One relapse with objective clinical evidence (history or present) of at least 2&#xD;
             lesions, and dissemination in time, demonstrated signs of disease activity ( new Gd+&#xD;
             lesion or new T2 lesion) in an MRI scan at least 3 months after the onset of that&#xD;
             clinical event.&#xD;
&#xD;
          -  One relapse and objective clinical evidence (history or present) of 1 lesion, and&#xD;
             dissemination in space, demonstrated by MRI (Barkhof/Tintoré criteria); or 2 MRI T2&#xD;
             lesions consistent with MS plus positive CSF, and dissemination in time, demonstrated&#xD;
             by signs of disease activity (new Gd+ lesion or new T2 lesion) in an MRI scan at least&#xD;
             3 months after the onset of that clinical event.&#xD;
&#xD;
               -  18 to 55 years of age&#xD;
&#xD;
               -  Score of 0-5.5 on the Kurtzke Expanded Disability Status Scale' (EDSS; see&#xD;
                  Appendix 16.1.1 [Protocol Appendix 4])&#xD;
&#xD;
               -  Naïve to immunomodulating therapies or previously treated with immunomodulating&#xD;
                  therapies other than any interferon (IFN) more than 30 days prior to the start of&#xD;
                  the study&#xD;
&#xD;
               -  If female of child-bearing potential, agreement to practice adequate&#xD;
                  contraception methods (IUCD, condoms, oral contraceptives, or other adequate&#xD;
                  barrier contraception)&#xD;
&#xD;
               -  Negative serum pregnancy test results.&#xD;
&#xD;
               -  Signed and dated statement of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant heart disease such as uncontrolled cardiac dysrhythmia, angina&#xD;
             pectoris, cardiomyopathy, or congestive heart failure&#xD;
&#xD;
          -  History of severe depression, suicide attempts, or current suicidal ideations&#xD;
&#xD;
          -  Clinically significant liver, renal, and bone marrow dysfunction as defined by any of&#xD;
             the following laboratory evaluations:&#xD;
&#xD;
          -  bone marrow dysfunction:&#xD;
&#xD;
               -  Hb &lt;8.5 g/dl&#xD;
&#xD;
               -  WBC &lt;2.5 x 109/L&#xD;
&#xD;
               -  platelet count &lt;125 x 109/L&#xD;
&#xD;
          -  renal dysfunction: creatinine &gt;1.8 mg/dL&#xD;
&#xD;
          -  liver dysfunction:&#xD;
&#xD;
               -  ASAT (SGOT) &gt;3xupper limit of normal&#xD;
&#xD;
               -  bilirubin &gt;2x upper limit of normal&#xD;
&#xD;
          -  Epilepsy not adequately controlled by treatment&#xD;
&#xD;
          -  Any conditions that could interfere with the MRI or any other evaluation in the study&#xD;
&#xD;
          -  Known allergy to human proteins including albumin and IFN, or to mannitol or&#xD;
             gadolinium&#xD;
&#xD;
          -  Participation in any clinical study within the past 30 days or use/intake of an&#xD;
             investigational drug within the last 3 months prior to study entry&#xD;
&#xD;
          -  Prior treatment with monoclonal antibody therapy, cladribine or total lymphoid&#xD;
             irradiation&#xD;
&#xD;
          -  Treatment with cytotoxic or immunosuppressive therapies (except systemic steroid or&#xD;
             adrenocorticotropic hormone [ACTH]) within 6 months prior to study entry; or systemic&#xD;
             steroid or ACTH within 1 month prior to study entry&#xD;
&#xD;
          -  Presence of monoclonal gammopathy&#xD;
&#xD;
          -  Inability to tolerate both NSAIDs and acetaminophen&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  History of alcohol or drug abuse&#xD;
&#xD;
          -  Inability to administer subcutaneous injections either by self or by caregiver&#xD;
&#xD;
          -  Medical, psychiatric or other conditions that compromise the patient's ability to give&#xD;
             informed consent, to understand the patient information, to comply with the study&#xD;
             protocol, or to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309-1465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89557-0035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <last_update_submitted>November 6, 2009</last_update_submitted>
  <last_update_submitted_qc>November 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Healthcare Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

